Novel targets for lung cancer therapy: Part II

Grace K. Dy, Alex Adjei

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

Lung cancer is the second most common form of cancer in the United States, and although it accounts for 15% of all cancers, it is the most lethal, accounting for approximately 28% of cancer deaths. In 2002, it is estimated that 177,000 new cases of lung cancer will be diagnosed in the United States, and an estimated 160,000 men and women will die from the disease. This mortality rate is greater than that attributable to colorectal, breast, and prostate cancer combined. Systemic treatments for lung cancer with standard chemotherapy agents are still relatively ineffective. Agents targeting novel proliferative and survival pathways in lung cancer are needed to improve treatment outcomes. In recent years, numerous agents inhibiting aberrant processes in tumor cells have undergone clinical evaluation. This review is the second of a two-part series that summarizes pertinent preclinical and clinical information on novel drugs that target critical abnormalities in lung cancer. In this article, agents that were developed to inhibit various aspects of tumor protein trafficking and protein degradation, cell cycle regulation, angiogenesis, and antigenicity are described. Future approaches to treatment are suggested.

Original languageEnglish (US)
Pages (from-to)3016-3028
Number of pages13
JournalJournal of Clinical Oncology
Volume20
Issue number13
DOIs
StatePublished - Jul 1 2002

Fingerprint

Lung Neoplasms
Neoplasms
Therapeutics
Protein Transport
Proteolysis
Colorectal Neoplasms
Prostatic Neoplasms
Cell Cycle
Breast Neoplasms
Drug Therapy
Survival
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Novel targets for lung cancer therapy : Part II. / Dy, Grace K.; Adjei, Alex.

In: Journal of Clinical Oncology, Vol. 20, No. 13, 01.07.2002, p. 3016-3028.

Research output: Contribution to journalReview article

Dy, Grace K. ; Adjei, Alex. / Novel targets for lung cancer therapy : Part II. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 13. pp. 3016-3028.
@article{b965c653769c4d54aebd7b6e1c46f772,
title = "Novel targets for lung cancer therapy: Part II",
abstract = "Lung cancer is the second most common form of cancer in the United States, and although it accounts for 15{\%} of all cancers, it is the most lethal, accounting for approximately 28{\%} of cancer deaths. In 2002, it is estimated that 177,000 new cases of lung cancer will be diagnosed in the United States, and an estimated 160,000 men and women will die from the disease. This mortality rate is greater than that attributable to colorectal, breast, and prostate cancer combined. Systemic treatments for lung cancer with standard chemotherapy agents are still relatively ineffective. Agents targeting novel proliferative and survival pathways in lung cancer are needed to improve treatment outcomes. In recent years, numerous agents inhibiting aberrant processes in tumor cells have undergone clinical evaluation. This review is the second of a two-part series that summarizes pertinent preclinical and clinical information on novel drugs that target critical abnormalities in lung cancer. In this article, agents that were developed to inhibit various aspects of tumor protein trafficking and protein degradation, cell cycle regulation, angiogenesis, and antigenicity are described. Future approaches to treatment are suggested.",
author = "Dy, {Grace K.} and Alex Adjei",
year = "2002",
month = "7",
day = "1",
doi = "10.1200/JCO.2002.02.112",
language = "English (US)",
volume = "20",
pages = "3016--3028",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Novel targets for lung cancer therapy

T2 - Part II

AU - Dy, Grace K.

AU - Adjei, Alex

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Lung cancer is the second most common form of cancer in the United States, and although it accounts for 15% of all cancers, it is the most lethal, accounting for approximately 28% of cancer deaths. In 2002, it is estimated that 177,000 new cases of lung cancer will be diagnosed in the United States, and an estimated 160,000 men and women will die from the disease. This mortality rate is greater than that attributable to colorectal, breast, and prostate cancer combined. Systemic treatments for lung cancer with standard chemotherapy agents are still relatively ineffective. Agents targeting novel proliferative and survival pathways in lung cancer are needed to improve treatment outcomes. In recent years, numerous agents inhibiting aberrant processes in tumor cells have undergone clinical evaluation. This review is the second of a two-part series that summarizes pertinent preclinical and clinical information on novel drugs that target critical abnormalities in lung cancer. In this article, agents that were developed to inhibit various aspects of tumor protein trafficking and protein degradation, cell cycle regulation, angiogenesis, and antigenicity are described. Future approaches to treatment are suggested.

AB - Lung cancer is the second most common form of cancer in the United States, and although it accounts for 15% of all cancers, it is the most lethal, accounting for approximately 28% of cancer deaths. In 2002, it is estimated that 177,000 new cases of lung cancer will be diagnosed in the United States, and an estimated 160,000 men and women will die from the disease. This mortality rate is greater than that attributable to colorectal, breast, and prostate cancer combined. Systemic treatments for lung cancer with standard chemotherapy agents are still relatively ineffective. Agents targeting novel proliferative and survival pathways in lung cancer are needed to improve treatment outcomes. In recent years, numerous agents inhibiting aberrant processes in tumor cells have undergone clinical evaluation. This review is the second of a two-part series that summarizes pertinent preclinical and clinical information on novel drugs that target critical abnormalities in lung cancer. In this article, agents that were developed to inhibit various aspects of tumor protein trafficking and protein degradation, cell cycle regulation, angiogenesis, and antigenicity are described. Future approaches to treatment are suggested.

UR - http://www.scopus.com/inward/record.url?scp=0036645063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036645063&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.02.112

DO - 10.1200/JCO.2002.02.112

M3 - Review article

C2 - 12089232

AN - SCOPUS:0036645063

VL - 20

SP - 3016

EP - 3028

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -